-
Cytosolic DNA and TDP-43 Homeostasis in ALS
2026-08-20
Yang and colleagues show that cytosolic DNA can reorganize TDP-43 into reversible condensates and, when persistent, drive nuclear depletion, KPNB1 sequestration, and increased production of a short TDP-43 isoform. The study connects DNA accumulation, DNA damage, and nuclear-envelope compromise with TDP-43 proteinopathy while providing experimentally testable models for neurodegeneration research.
-
CD28–ARS2 Control of CD8+ T Cell Metabolism
2026-08-20
Holling and colleagues identify a CD28–ARS2 signaling axis that reshapes alternative splicing of PKM in activated CD8+ T cells, favoring PKM2 and supporting glucose-use flexibility, interferon-γ production, and antitumor activity. The study connects costimulatory signaling to post-transcriptional metabolic control and provides a framework for separating splicing-dependent effects from canonical PI3K-mediated glucose regulation.
-
Meropenem Trihydrate: Reading Resistance by Metabolomics
2026-08-19
Meropenem trihydrate is more than a broad-spectrum carbapenem antibiotic: it can anchor controlled studies of bacterial physiology, resistance phenotypes, and infection-model confounding. This article translates recent LC-MS/MS metabolomics findings into practical assay decisions for antibiotic resistance studies and bacterial infection treatment research.
-
2-Hydroxypropyl-β-cyclodextrin Workflow Guide
2026-08-19
2-Hydroxypropyl-β-cyclodextrin (SKU B6413) is a water-soluble cyclic oligosaccharide used to improve the handling of poorly water-soluble, hydrophobic compounds, particularly molecules containing aromatic or phenyl groups. It is appropriate for pharmaceutical solubility improvement, drug formulation excipient workflows, and related biochemical formulation studies, but the supplied dossier does not support therapeutic claims or unrelated applications.
-
BCL-XL inhibitor A-1155463: Applied Workflows
2026-08-18
Build mechanism-led cancer assays with A-1155463, from BCL-XL dependency mapping and apoptosis profiling to exploratory tumor studies. Its nanomolar affinity, DMSO compatibility, and reported platelet recovery profile make it useful for separating pathway activity from formulation and model-specific artifacts.
-
AEBSF.HCl in Protease-Centered Cell Death Assays
2026-08-18
AEBSF.HCl is an irreversible serine protease inhibitor with applications spanning APP processing, immune-mediated lysis, and cell-death research. This article explains how to use it as a mechanistic control without confusing serine protease activity with cathepsin B-driven lysosomal permeabilization.
-
DAPI (hydrochloride) for DNA Assays
2026-08-17
DAPI (hydrochloride) provides a practical route to nuclear imaging, chromosome staining, and DNA-content measurements across fixed and live-cell workflows. This guide connects assay setup and troubleshooting with the glabridin–gold(I) immunomodulation study, showing where DAPI strengthens interpretation without being mistaken for a standalone mechanistic readout.
-
IEM 1460 AMPA Receptor Blocker Workflows
2026-08-17
IEM 1460 enables selective AMPA receptor inhibition in excitotoxicity, synaptic transmission, and neuroprotection experiments. This guide translates receptor pharmacology and findings from a dual-target seizure study into practical assay design, controls, and troubleshooting decisions.
-
ATM Inhibition and Fenofibrate in HGSOC
2026-08-16
The reference study identifies a metabolic vulnerability in high-grade serous ovarian cancer by showing that ATM inhibition can cooperate with fenofibrate, a PPARα agonist, to induce senescence. Its findings extend ATM-targeted therapy beyond combinations with conventional DNA-damaging agents and suggest that ATM expression, metabolic state, and senescence response should be evaluated together in preclinical models.
-
RHEB Neddylation Activates mTORC1 in Liver Cancer
2026-08-15
The reference study identifies RHEB as a non-cullin substrate of the UBE2F–SAG neddylation machinery and shows that modification at K169 strengthens lysosomal localization, GTP binding, and mTORC1 activation. Genetic evidence from cell and liver-specific models links this pathway to steatosis, hepatocellular tumorigenesis, and patient-survival associations.
-
Quinolone–Coumarin Hybrids Against Toxoplasma gondii
2026-08-14
A 2024 Acta Parasitologica study evaluated twelve quinolone–coumarin hybrids derived from fluoroquinolones and novobiocin against intracellular Toxoplasma gondii. QC1, QC3, QC6, and novobiocin showed favorable selectivity and reduced infection, parasite proliferation, and plaque formation in vitro, supporting further lead-optimization studies while leaving target validation and in vivo efficacy unresolved.
-
Triiodothyronine in Cell Viability Assays
2026-08-14
Learn how Triiodothyronine (T3), SKU C6407, can be incorporated into reproducible viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers solubility, vehicle controls, assay interpretation, protocol planning, and reagent-selection criteria for thyroid hormone research.
-
Forskolin Workflows for cAMP and Vascular Research
2026-08-13
Build reproducible cAMP perturbation workflows with Forskolin for stem-cell, neuroendocrine, and vascular assays. This guide connects direct adenylate cyclase activation with the CD36–autophagy-lysosomal framework emerging from vascular injury research, while clearly separating established evidence from testable extensions.
-
Cy5 Goat Anti-Rabbit IgG: Mechanism to Readout
2026-08-13
Learn how the Cy5 Goat Anti-Rabbit IgG (H+L) Antibody converts rabbit-primary assays into interpretable fluorescence data. This guide connects secondary-antibody design with the ASB3–MAVS antiviral pathway while emphasizing controls, signal architecture, and assay limitations.
-
BGJ398: A Developmental Lens on FGFR2 Assays
2026-08-12
BGJ398 (NVP-BGJ398) is a selective FGFR1/2/3 inhibitor with broad value in oncology research. This article shows how developmental evidence on Fgf10–Fgfr2 signaling can sharpen model selection, endpoint timing, and interpretation of FGFR assays.